Tularemia vaccines: Recent developments and remaining hurdles

Future Microbiology

Volumn 6, Issue 4, 2011, Pages 391-405

  Conlan, J Wayne ^a  

^a NATIONAL RESEARCH COUNCIL CANADA   (Canada)

Author keywords

aerosol; animal model; Animal Rule; Francisella tularensis; tularemia; vaccines

Indexed keywords

BACTERIAL POLYSACCHARIDE; BACTERIAL PROTEIN; BACTERIUM LIPOPOLYSACCHARIDE; CHOLERA TOXIN B SUBUNIT; FREUND ADJUVANT; IGLC PROTEIN; ISCOM; KATG PROTEIN; LIPID A; LIVE VACCINE; OUTER MEMBRANE PROTEIN; SODB PROTEIN; TETANUS TOXOID; TULAREMIA VACCINE; UNCLASSIFIED DRUG;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIBODY RESPONSE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BACTERIAL IMMUNITY; BACTERIAL STRAIN; BACTERIAL VIRULENCE; CELLULAR IMMUNITY; CPG ISLAND; CYTOKINE RESPONSE; DRUG APPROVAL; DRUG EFFICACY; DRUG FEVER; DRUG SAFETY; EXPERIMENTAL INFECTION; FLU LIKE SYNDROME; FRANCISELLA TULARENSIS; GRAM POSITIVE INFECTION; GRANULOMA; HUMAN; LUNG INFECTION; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; SPLENOMEGALY; TULAREMIA; VACCINATION;

ANIMALS; BACTERIAL VACCINES; FRANCISELLA TULARENSIS; HUMANS; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; TULAREMIA; VACCINES, ATTENUATED;

ANIMALIA; BACTERIA (MICROORGANISMS); FRANCISELLA TULARENSIS; FRANCISELLA TULARENSIS SUBSP. TULARENSIS; MAMMALIA; MUS;

EID: 79955641277     PISSN: 17460913     EISSN: None     Source Type: Journal    
DOI: 10.2217/fmb.11.22     Document Type: Review

References (97)

1. Sjostedt A: Tularemia: history, epidemiology, pathogen physiology, and clinical manifestations. Ann. NY Acad. Sci. 1105, 1-29 (2007). (Pubitemid 47507090)
2. Saslaw S, Eigelsbach HT, Prior JA, Wilson HE, Carhart S: Tularemia vaccine study. II. Respiratory challenge. Arch. Intern. Med. 107, 702-714 (1961).
3. Dennis DT, Inglesby TV, Henderson DA et al.: Tularemia as a biological weapon: medical and public health management. JAMA 285, 2763-2773 (2001). (Pubitemid 32525374)
4. Conlan JW, Shen H, Webb A, Perry MB: Mice vaccinated with the O-antigen of Francisella tularensis LVS lipopolysaccharide conjugated to bovine serum albumin develop varying degrees of protective immunity against systemic or aerosol challenge with virulent type A and type B strains of the pathogen. Vaccine 20, 3465-3471 (2002). (Pubitemid 35248070)
5. Prior JL, Prior RG, Hitchen PG et al.: Characterization of the O antigen gene cluster and structural analysis of the O antigen of Francisella tularensis subsp. tularensis. J. Med. Microbiol. 52, 845-851 (2003). (Pubitemid 37297312)
6. Eigelsbach HT, Downs CM: Prophylactic effectiveness of live and killed tularemia vaccines. I. Production of vaccine and evaluation in the white mouse and guinea pig. J. Immunol. 87, 415-425 (1961).
7. Pasetti MF, Cuberos L, Horn TL et al.: An improved Francisella tularensis live vaccine strain (LVS) is well tolerated and highly immunogenic when administered to rabbits in escalating doses using various immunization routes. Vaccine 26, 1773-1785 (2008).
8. McCrumb FR: Aerosol infection of man with Pasteurella tularensis. Bacteriol. Rev. 25, 262-267 (1961).
9. Hornick RB, Eigelsbach HT: Aerogenic immunization of man with live Tularemia vaccine. Bacteriol. Rev. 30, 532-538 (1966).
10. Burke DS: Immunization against tularemia: analysis of the effectiveness of live Francisella tularensis vaccine in prevention of laboratory-acquired tularemia. J. Infect. Dis. 135, 55-60 (1977).
11. Tarnvik A, Lofgren S: Stimulation of human lymphocytes by a vaccine strain of Francisella tularensis. Infect. Immun. 12, 951-957 (1975).
12. Tarnvik A, Holm SE: Stimulation of subpopulations of human lymphocytes by a vaccine strain of Francisella tularensis. Infect. Immun. 20, 698-704 (1978). (Pubitemid 8352007)
13. Koskela P, Herva E: Cell-mediated and humoral immunity induced by a live Francisella tularensis vaccine. Infect. Immun. 36, 983-989 (1982). (Pubitemid 12124812)
14. Tarnvik A, Sandstrom G, Lofgren S: Time of lymphocyte response after onset of tularemia and after tularemia vaccination. J. Clin. Microbiol. 10, 854-860 (1979). (Pubitemid 10215448)
15. Sandstrom G, Tarnvik A, Wolf-Watz H: Immunospecific T-lymphocyte stimulation by membrane proteins from Francisella tularensis. J. Clin. Microbiol. 25, 641-644 (1987). (Pubitemid 17041859)
16. Fuller CL, Brittingham KC, Porter MW et al.: Transcriptome analysis of human immune responses following live vaccine strain (LVS) Francisella tularensis vaccination. Mol. Immunol. 44, 3173-3184 (2007). (Pubitemid 46610506)
17. Karttunen R, Andersson G, Ekre HP et al.: Interleukin 2 and g interferon production, interleukin 2 receptor expression, and DNA synthesis induced by tularemia antigen in vitro after natural infection or vaccination. J. Clin. Microbiol. 25, 1074-1078 (1987). (Pubitemid 17079594)
18. Sjostedt A, Eriksson M, Sandstrom G, Tarnvik A: Various membrane proteins of Francisella tularensis induce interferon-g production in both CD4+ and CD8+ T cells of primed humans. Immunology 76, 584-592 (1992).
19. Salerno-Goncalves R, Hepburn MJ, Bavari S, Sztein MB: Generation of heterogeneous memory T cells by live attenuated tularemia vaccine in humans. Vaccine 28, 195-206 (2009).
20. El Sahly HM, Atmar RL, Patel SM et al.: Safety, reactogenicity and immunogenicity of Francisella tularensis live vaccine strain in humans. Vaccine 27, 4905-4911 (2009).
21. Waag DM, McKee KT Jr, Sandstrom G et al.: Cell-mediated and humoral immune responses after vaccination of human volunteers with the live vaccine strain of Francisella tularensis. Clin. Diagn. Lab. Immunol. 2, 143-148 (1995).
22. Elkins KL, Cowley SC, Bosio CM: Innate and adaptive immunity to Francisella. Ann. NY Acad. Sci. 1105, 284-324 (2007). (Pubitemid 47507095)
23. Twine SM, Petit MD, Fulton KM, House RV, Conlan JW: Immunoproteomics analysis of the murine antibody response to vaccination with an improved Francisella tularensis live vaccine strain (LVS). PLoS ONE 5(4), E10000 (2010).
24. Cowley SC, Meierovics AI, Frelinger JA, Iwakura Y, Elkins KL: Lung CD4- CD8- double-negative T cells are prominent producers of IL-17A and IFN-g during primary respiratory murine infection with Francisella tularensis live vaccine strain. J. Immunol. 184, 5791-5801 (2010).
25. Conlan JW, Oyston PC: Vaccines against Francisella tularensis. Ann. NY Acad. Sci. 1105, 325-350 (2007). (Pubitemid 47507093)
26. Wu TH, Hutt JA, Garrison KA, Berliba LS, Zhou Y, Lyons CR: Intranasal vaccination induces protective immunity against intranasal infection with virulent Francisella tularensis biovar A. Infect. Immun. 73, 2644-2654 (2005). (Pubitemid 40570329)
27. Conlan JW, Shen H, Kuolee R, Zhao X, Chen W: Aerosol-, but not intradermal-immunization with the live vaccine strain of Francisella tularensis protects mice against subsequent aerosol challenge with a highly virulent type A strain of the pathogen by an ab T cell- and interferon g- dependent mechanism. Vaccine 23, 2477-2485 (2005).
28. Twine SM, Petit MD, Shen H, Mykytczuk NC, Kelly JF, Conlan JW: Immunoproteomic analysis of the murine antibody response to successful and failed immunization with live anti-Francisella vaccines. Biochem. Biophys. Res. Commun. 346, 999-1008 (2006).
29. Chen W, Shen H, Webb A, KuoLee R, Conlan JW: Tularemia in BALB/c and C57BL/6 mice vaccinated with Francisella tularensis LVS and challenged intradermally, or by aerosol with virulent isolates of the pathogen: protection varies depending on pathogen virulence, route of exposure, and host genetic background. Vaccine 21, 3690-3700 (2003). (Pubitemid 37345131)
30. Wu TH, Zsemlye JL, Statom GL et al.: Vaccination of Fischer 344 rats against pulmonary infections by Francisella tularensis type A strains. Vaccine 27, 4684-4693 (2009).
31. Eigelsbach HT, Tulis JJ, Overholt EL, Griffith WR: Aerogenic immunization of the monkey and guinea pig with live tularemia vaccine. Proc. Soc. Exp. Biol. Med. 108, 732-734 (1961).
32. Saslaw S, Carhart S: Studies with tularemia vaccines in volunteers. III. Serologic aspects following intracutaneous or respiratory challenge in both vaccinated and nonvaccinated volunteers. Am. J. Med. Sci. 241, 689-699 (1961).
33. Eyles JE, Hartley MG, Laws TR, Oyston PC, Griffin KF, Titball RW: Protection afforded against aerosol challenge by systemic immunisation with inactivated Francisella tularensis live vaccine strain (LVS). Microb. Pathog. 44, 164-168 (2008). (Pubitemid 350297674)
34. Quarry JE, Isherwood KE, Michell SL, Diaper H, Titball RW, Oyston PC: A Francisella tularensis subspecies novicida purF mutant, but not a purA mutant, induces protective immunity to tularemia in mice. Vaccine 25, 2011-2018 (2007). (Pubitemid 46227681)
35. Shen H, Chen W, Conlan JW: Mice sublethally infected with Francisella novicida U112 develop only marginal protective immunity against systemic or aerosol challenge with virulent type A or B strains of F. tularensis. Microb. Pathog. 37, 107-110 (2004). (Pubitemid 39106845)
36. Cong Y, Yu JJ, Guentzel MN et al.: Vaccination with a defined Francisella tularensis subsp. novicida pathogenicity island mutant (DeltaiglB) induces protective immunity against homotypic and heterotypic challenge. Vaccine 27, 5554-5561 (2009).
37. KuoLee R, Harris G, Conlan JW, Chen W: Oral immunization of mice with the live vaccine strain (LVS) of Francisella tularensis protects mice against respiratory challenge with virulent type A F. tularensis. Vaccine 25, 3781-3791 (2007). (Pubitemid 46589759)
38. Ray HJ, Cong Y, Murthy AK et al.: Oral live vaccine strain-induced protective immunity against pulmonary Francisella tularensis challenge is mediated by CD4+ T cells and antibodies, including immunoglobulin A. Clin. Vaccine Immunol. 16, 444-452 (2009).
39. Shen H, Chen W, Conlan JW: Susceptibility of various mouse strains to systemically- or aerosol-initiated tularemia by virulent type A Francisella tularensis before and after immunization with the attenuated live vaccine strain of the pathogen. Vaccine 22, 2116-2121 (2004). (Pubitemid 38626048)
40. Anderson RV, Crane DD, Bosio CM: Long lived protection against pneumonic tularemia is correlated with cellular immunity in peripheral, not pulmonary, organs. Vaccine 28, 6562-6572 (2010).
41. Green M, Choules G, Rogers D, Titball RW: Efficacy of the live attenuated Francisella tularensis vaccine (LVS) in a murine model of disease. Vaccine 23, 2680-2686 (2005). (Pubitemid 40380813)
42. Jia Q, Lee BY, Bowen R, Dillon BJ, Som SM, Horwitz MA: A Francisella tularensis Live Vaccine Strain mutant with a deletion in capB, encoding a putative capsular biosynthesis protein, is significantly more attenuated than LVS yet induces potent protective immunity in mice against F. tularensis challenge. Infect. Immun. 78(10), 4341-4355 (2010).
43. Pechous RD, McCarthy TR, Mohapatra NP et al.: A Francisella tularensis Schu S4 purine auxotroph is highly attenuated in mice but offers limited protection against homologous intranasal challenge. PLoS ONE 3(6), E2487 (2008).
44. Qin A, Scott DW, Thompson JA, Mann BJ: Identification of an essential Francisella tularensis subsp. tularensis virulence factor. Infect. Immun. 77, 152-161 (2009).
45. Gregory SH, Chen WH, Mott S et al.: Detoxified endotoxin vaccine (J5dLPS/OMP) protects mice against lethal respiratory challenge with Francisella tularensis SchuS4. Vaccine 28, 2908-2915 (2010).
46. Rawool DB, Bitsaktsis C, Li Y et al.: Utilization of Fc receptors as a mucosal vaccine strategy against an intracellular bacterium, Francisella tularensis. J. Immunol. 180, 5548-5557 (2008).
47. Bitsaktsis C, Rawool DB, Li Y, Kurkure NV, Iglesias B, Gosselin EJ: Differential requirements for protection against mucosal challenge with Francisella tularensis in the presence versus absence of cholera toxin B and inactivated F. tularensis. J. Immunol. 182, 4899-4909 (2009).
48. Huntley JF, Conley PG, Rasko DA, Hagman KE, Apicella MA, Norgard MV: Native outer membrane proteins protect mice against pulmonary challenge with virulent type A Francisella tularensis. Infect. Immun. 76, 3664-3671 (2008).
49. Bakshi CS, Malik M, Mahawar M et al.: An improved vaccine for prevention of respiratory tularemia caused by Francisella tularensis SchuS4 strain. Vaccine 26, 5276-5288 (2008).
50. Sebastian S, Pinkham JT, Lynch JG et al.: Cellular and humoral immunity are synergistic in protection against types A and B Francisella tularensis. Vaccine 27, 597-605 (2009).
51. Jia Q, Lee BY, Clemens DL, Bowen RA, Horwitz MA: Recombinant attenuated Listeria monocytogenes vaccine expressing Francisella tularensis IglC induces protection in mice against aerosolized Type A F. tularensis. Vaccine 27, 1216-1229 (2009).
52. Conlan JW, Shen H, Golovliov I et al.: Differential ability of novel attenuated targeted deletion mutants of Francisella tularensis subspecies tularensis strain SCHU S4 to protect mice against aerosol challenge with virulent bacteria: effects of host background and route of immunization. Vaccine 28, 1824-1831 (2010).
53. Shen H, Harris G, Chen W, Sjostedt A, Ryden P, Conlan W: Molecular immune responses to aerosol challenge with Francisella tularensis in mice inoculated with live vaccine candidates of varying efficacy. PLoS ONE 5(10), E13349 (2010).
54. Williamson ED, Duchars MG, Kohberger R: Predictive models and correlates of protection for testing biodefence vaccines. Expert Rev. Vaccines 9, 527-537 (2010).
55. Barrett AD, Beasley DW: Development pathway for biodefense vaccines. Vaccine 27(Suppl. 4), D2-D7 (2009).
56. Horne AD, Clifford J, Goldenthal KL, Kleppinger C, Lachenbruch PA: Preventive vaccines against bioterrorism: evaluation of efficacy and safety. Vaccine 23, 84-90 (2004). (Pubitemid 39446363)
57. Gronvall GK, Trent D, Borio L, Brey R, Nagao L: The FDA animal efficacy rule and biodefense. Nat. Biotechnol. 25, 1084-1087 (2007). (Pubitemid 47538099)
58. Saslaw S, Eigelsbach HT, Wilson HE, Prior JA, Carhart S: Tularemia vaccine study. I. Intracutaneous challenge. Arch. Intern. Med. 107, 689-701 (1961).
59. Matyas BT, Nieder HS, Telford SR 3rd: Pneumonic tularemia on Martha's Vineyard: clinical, epidemiologic, and ecological characteristics. Ann. NY Acad. Sci. 1105, 351-377 (2007). (Pubitemid 47507094)
60. Lillie RD, Francis E: The pathology of tularemia in man. Natl Inst. Health Bull. 167, 1-82 (1936).
61. Clemens DL, Horwitz MA: Uptake and intracellular fate of Francisella tularensis in human macrophages. Ann. NY Acad. Sci. 1105, 160-186 (2007). (Pubitemid 47507083)
62. Bosio CM, Bielefeldt-Ohmann H, Belisle JT: Active suppression of the pulmonary immune response by Francisella tularensis Schu4. J. Immunol. 178, 4538-4547 (2007). (Pubitemid 46492406)
63. Conlan JW, Chen W, Shen H, Webb A, KuoLee R: Experimental tularemia in mice challenged by aerosol or intradermally with virulent strains of Francisella tularensis: bacteriologic and histopathologic studies. Microb. Pathog. 34, 239-248 (2003). (Pubitemid 36539370)
64. Kadzhaev K, Zingmark C, Golovliov I et al.: Identification of genes contributing to the virulence of Francisella tularensis SCHU S4 in a mouse intradermal infection model. PLoS ONE 4(5), E5463 (2009).
65. Meibom KL, Charbit A: The unraveling panoply of Francisella tularensis virulence attributes. Curr. Opin. Microbiol. 13, 11-17 (2010).
66. Thomas RM, Titball RW, Oyston PC et al.: The immunologically distinct O antigens from Francisella tularensis subspecies tularensis and Francisella novicida are both virulence determinants and protective antigens. Infect. Immun. 75, 371-378 (2007). (Pubitemid 46047913)
67. Apicella MA, Post DM, Fowler AC et al.: Identification, characterization and immunogenicity of an O-antigen capsular polysaccharide of Francisella tularensis. PLoS ONE 5, E11060 (2010).
68. Sandstrom G, Sjostedt A, Johansson T, Kuoppa K, Williams JC: Immunogenicity and toxicity of lipopolysaccharide from Francisella tularensis LVS. FEMS Microbiol. Immunol. 5, 201-210 (1992).
69. Kieffer TL, Cowley S, Nano FE, Elkins KL: Francisella novicida LPS has greater immunobiological activity in mice than F. tularensis LPS, and contributes to F. novicida murine pathogenesis. Microbes Infect. 5, 397-403 (2003). (Pubitemid 36549181)
70. Chen W, KuoLee R, Shen H, Busa M, Conlan JW: Toll-like receptor 4 (TLR4) does not confer a resistance advantage on mice against low-dose aerosol infection with virulent type A Francisella tularensis. Microb. Pathog. 37, 185-191 (2004). (Pubitemid 39349042)
71. Barker JR, Klose KE: Molecular and genetic basis of pathogenesis in Francisella tularensis. Ann. NY Acad. Sci. 1105, 138-159 (2007). (Pubitemid 47507091)
72. Raymond CR, Conlan JW: Differential susceptibility of Sprague-Dawley and Fischer 344 rats to infection by Francisella tularensis. Microb. Pathog. 46, 231-234 (2009).
73. Conlan JW, Zhao X, Harris G et al.: Molecular immunology of experimental primary tularemia in mice infected by respiratory or intradermal routes with type A Francisella tularensis. Mol. Immunol. 45, 2962-2969 (2008).
74. Twenhafel NA, Alves DA, Purcell BK: Pathology of inhalational Francisella tularensis spp. tularensis SCHU S4 infection in African green monkeys (Chlorocebus aethiops). Vet. Pathol. 46, 698-706 (2009).
75. Nelson M, Lever MS, Dean RE et al.: Characterisation of lethal inhalational infection with Francisella tularensis in the common marmoset (Callithrix jacchus). J. Med. Microbiol. 59(Pt 9), 1107-1113 (2010).
76. Chen W, Kuolee R, Austin JW, Shen H, Che Y, Conlan JW: Low dose aerosol infection of mice with virulent type A Francisella tularensis induces severe thymus atrophy and CD4+CD8+ thymocyte depletion. Microb. Pathog. 39, 189-196 (2005). (Pubitemid 41643133)
77. Andersson H, Hartmanova B, Kuolee R et al.: Transcriptional profiling of host responses in mouse lungs following aerosol infection with type A Francisella tularensis. J. Med. Microbiol. 55, 263-271 (2006).
78. Lyons CR, Wu TH: Animal models of Francisella tularensis infection. Ann. NY Acad. Sci. 1105, 238-265 (2007). (Pubitemid 47507085)
79. Chen W, KuoLee R, Shen H, Conlan JW: Susceptibility of immunodeficient mice to aerosol and systemic infection with virulent strains of Francisella tularensis. Microb. Pathog. 36, 311-318 (2004). (Pubitemid 38543058)
80. Fulop M, Mastroeni P, Green M, Titball RW: Role of antibody to lipopolysaccharide in protection against low- and high-virulence strains of Francisella tularensis. Vaccine 19, 4465-4472 (2001). (Pubitemid 32718670)
81. Cowley SC, Elkins KL: Multiple T cell subsets control Francisella tularensis LVS intracellular growth without stimulation through macrophage interferon g receptors. J. Exp. Med. 198, 379-389 (2003). (Pubitemid 36976051)
82. Fortier AH, Polsinelli T, Green SJ, Nacy CA: Activation of macrophages for destruction of Francisella tularensis: identification of cytokines, effector cells, and effector molecules. Infect. Immun. 60, 817-825 (1992).
83. Cowley SC, Goldberg MF, Ho JA, Elkins KL: The membrane form of tumor necrosis factor is sufficient to mediate partial innate immunity to Francisella tularensis live vaccine strain. J. Infect. Dis. 198, 284-292 (2008). (Pubitemid 352019295)
84. Collazo CM, Meierovics AI, De Pascalis R, Wu TH, Lyons CR, Elkins KL: T cells from lungs and livers of Francisella tularensis-immune mice control the growth of intracellular bacteria. Infect. Immun. 77, 2010-2021 (2009).
85. Boaz MJ, Hayes P, Tarragona T et al.: Concordant proficiency in measurement of T-cell immunity in human immunodeficiency virus vaccine clinical trials by peripheral blood mononuclear cell and enzyme-linked immunospot assays in laboratories from three continents. Clin. Vaccine Immunol. 16, 147-155 (2009).
86. Havlasova J, Hernychova L, Halada P et al.: Mapping of immunoreactive antigens of Francisella tularensis live vaccine strain. Proteomics 2, 857-867 (2002). (Pubitemid 34803969)
87. Havlasova J, Hernychova L, Brychta M et al.: Proteomic analysis of anti-Francisella tularensis LVS antibody response in murine model of tularemia. Proteomics 5, 2090-2103 (2005). (Pubitemid 40770573)
88. Janovska S, Pavkova I, Hubalek M, Lenco J, Macela A, Stulik J: Identification of immunoreactive antigens in membrane proteins enriched fraction from Francisella tularensis LVS. Immunol. Lett. 108, 151-159 (2007). (Pubitemid 46198959)
89. Eyles JE, Unal B, Hartley MG et al.: Immunodominant Francisella tularensis antigens identified using proteome microarray. Proteomics 7, 2172-2183 (2007). (Pubitemid 47067203)
90. Kirimanjeswara GS, Olmos S, Bakshi CS, Metzger DW: Humoral and cell-mediated immunity to the intracellular pathogen Francisella tularensis. Immunol. Rev. 225, 244-255 (2008).
91. Nelson M, Lever MS, Savage VL et al.: Establishment of lethal inhalational infection with Francisella tularensis (tularaemia) in the common marmoset (Callithrix jacchus). Int. J. Exp. Pathol. 90, 109-118 (2009).
92. Hornby RJ, Pearce PC, Bowditch AP, Scott L, Griffiths GD: Multiple vaccine and pyridostigmine bromide interactions in the common marmoset Callithrix jacchus: immunological and endocrinological effects. Int. Immunopharmacol. 6, 1765-1779 (2006). (Pubitemid 44557186)
93. Kametani Y, Suzuki D, Kohu K et al.: Development of monoclonal antibodies for analyzing immune and hematopoietic systems of common marmoset. Exp. Hematol. 37, 1318-1329 (2009).
94. Zahn RC, Rett MD, Li M et al.: Suppression of adaptive immune responses during primary SIV infection of sabaeus African green monkeys delays partial containment of viremia but does not induce disease. Blood 115, 3070-3078 (2010).
95. Beaumier CM, Harris LD, Goldstein S et al.: CD4 downregulation by memory CD4+ T cells in vivo renders African green monkeys resistant to progressive SIVagm infection. Nat. Med. 15, 879-885 (2009).
96. Petrovas C, Price DA, Mattapallil J et al.: SIV-specific CD8+ T cells express high levels of PD1 and cytokines but have impaired proliferative capacity in acute and chronic SIVmac251 infection. Blood 110, 928-936 (2007). (Pubitemid 47267431)
97. Hornick RB, Dawkins AT, Eigelsbach HT, Tulis JJ: Oral tularemia vaccine in man. Antimicrob. Agents Chemother. 6, 11-14 (1966).